Enimmune Corporation (TPEX:6564)

Market Cap	622.00M -57.5%
Revenue (ttm)	53.45M +26.6%
Net Income	-120.88M
EPS	-1.68
Shares Out	40.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,001
Open	15.35
Previous Close	15.30
Day's Range	15.25 - 15.55
52-Week Range	14.90 - 23.90
Beta	0.26
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Enimmune

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6564

Financial Performance

In 2025, Enimmune's revenue was 48.19 million, an increase of 20.74% compared to the previous year's 39.92 million. Losses were -164.35 million, 4.32% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 15, 2026

Data Sources Report a data error